JP2024507221A5 - - Google Patents
Info
- Publication number
- JP2024507221A5 JP2024507221A5 JP2023550043A JP2023550043A JP2024507221A5 JP 2024507221 A5 JP2024507221 A5 JP 2024507221A5 JP 2023550043 A JP2023550043 A JP 2023550043A JP 2023550043 A JP2023550043 A JP 2023550043A JP 2024507221 A5 JP2024507221 A5 JP 2024507221A5
- Authority
- JP
- Japan
- Prior art keywords
- braf
- cancer
- pharmaceutically acceptable
- acceptable salt
- combination according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163151425P | 2021-02-19 | 2021-02-19 | |
| US63/151,425 | 2021-02-19 | ||
| US202163173158P | 2021-04-09 | 2021-04-09 | |
| US63/173,158 | 2021-04-09 | ||
| PCT/US2022/016962 WO2022178244A1 (en) | 2021-02-19 | 2022-02-18 | Combination of raf inhibitor and mek inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024507221A JP2024507221A (ja) | 2024-02-16 |
| JP2024507221A5 true JP2024507221A5 (https=) | 2025-02-27 |
Family
ID=82931723
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023550043A Pending JP2024507221A (ja) | 2021-02-19 | 2022-02-18 | Ｒａｆ阻害剤とｍｅｋ阻害剤の組合せ |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240058338A1 (https=) |
| EP (1) | EP4294400A4 (https=) |
| JP (1) | JP2024507221A (https=) |
| KR (1) | KR20230147136A (https=) |
| AU (1) | AU2022223437A1 (https=) |
| CA (1) | CA3211167A1 (https=) |
| IL (1) | IL305250A (https=) |
| MX (1) | MX2023009642A (https=) |
| WO (1) | WO2022178244A1 (https=) |
| ZA (1) | ZA202307921B (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023056063A1 (en) * | 2021-10-01 | 2023-04-06 | Day One Biopharmaceuticals, Inc. | Raf kinase inhibitors for treating tumors harboring gene fusions |
| WO2025106686A1 (en) * | 2023-11-15 | 2025-05-22 | Day One Biopharmaceuticals, Inc. | Methods of treating pediatric low-grade glioma |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2868954A1 (en) * | 2012-03-30 | 2013-10-03 | Takeda Pharmaceutical Company Limited | Administration of a raf inhibitor and a mek inhibitor in the treatment of melanoma |
| US10668055B2 (en) * | 2013-12-20 | 2020-06-02 | Biomed Valley Discoveries, Inc. | Cancer treatment using combinations of ERK and RAF inhibitors |
| UY36046A (es) * | 2014-03-26 | 2015-10-30 | Millennium Pharm Inc | Formulaciones farmacéuticas, procesos para la preparación y métodos de uso |
| WO2016025648A1 (en) * | 2014-08-13 | 2016-02-18 | Celgene Avilomics Research, Inc. | Combinations of an erk inhibitor and a raf inhibitor and related methods |
| KR102811888B1 (ko) * | 2017-09-08 | 2025-05-27 | 에프. 호프만-라 로슈 아게 | 암의 진단 및 치료 방법 |
-
2022
- 2022-02-18 MX MX2023009642A patent/MX2023009642A/es unknown
- 2022-02-18 JP JP2023550043A patent/JP2024507221A/ja active Pending
- 2022-02-18 WO PCT/US2022/016962 patent/WO2022178244A1/en not_active Ceased
- 2022-02-18 AU AU2022223437A patent/AU2022223437A1/en not_active Abandoned
- 2022-02-18 IL IL305250A patent/IL305250A/en unknown
- 2022-02-18 KR KR1020237031421A patent/KR20230147136A/ko active Pending
- 2022-02-18 EP EP22756995.1A patent/EP4294400A4/en active Pending
- 2022-02-18 CA CA3211167A patent/CA3211167A1/en active Pending
-
2023
- 2023-08-15 ZA ZA2023/07921A patent/ZA202307921B/en unknown
- 2023-08-16 US US18/450,638 patent/US20240058338A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7114575B2 (ja) | Ｒａｆ阻害剤及びｅｒｋ阻害剤を含む治療用組合せ | |
| Drilon et al. | A phase I/Ib trial of the VEGFR-sparing multikinase RET inhibitor RXDX-105 | |
| JP2019532051A5 (https=) | ||
| JP7328151B2 (ja) | Ｈｅｒ２陽性がんの処置 | |
| JP6126069B2 (ja) | 癌の分類および使用法 | |
| Matheson et al. | Glucocorticoids and selumetinib are highly synergistic in RAS pathway-mutated childhood acute lymphoblastic leukemia through upregulation of BIM | |
| TW202317122A (zh) | Erk1/2及kras g12c抑制劑之組合療法 | |
| CN106456635A (zh) | Mdm2抑制剂的间歇给药 | |
| JP2014505658A5 (https=) | ||
| JP2024507221A5 (https=) | ||
| Aydemirli et al. | Targeting EML4-ALK gene fusion variant 3 in thyroid cancer | |
| US20250127759A1 (en) | Methods and dosing regimens comprising a cdk2 inhibitor for the treatment of cancer | |
| TW202302112A (zh) | 索托拉西布給藥方案 | |
| WO2022150628A1 (en) | Use of a kras g12c inhibitor in treating cancers | |
| US20240261289A1 (en) | Sotorasib dosing regimen | |
| Janku et al. | Dose‐escalation study of vemurafenib with sorafenib or crizotinib in patients with BRAF‐mutated advanced cancers | |
| JP2026053570A (ja) | Ｋｒａｓ ｇ１２ｃ変異を含む癌を治療するためのソトラシブ及びｅｇｆｒ抗体 | |
| Cappuzzo et al. | MAPK Pathway–Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT Trial | |
| Malhotra et al. | Management of KRAS-mutated non-small cell lung cancer. | |
| CA3244127A1 (en) | USE OF NIRAPARIB FOR THE TREATMENT OF BRAIN CANCER | |
| CN120282786A (zh) | 治疗晚期实体肿瘤的方法 | |
| TW202304438A (zh) | 使用貝伐拉非尼及考比替尼或使用貝伐拉非尼、考比替尼及阿替利珠單抗的組合療法 | |
| Grodkiewicz et al. | Optimizing treatment strategies for a MET exon 14 skipping mutation in non-small-cell lung cancer: a case report of sequential immunotherapy and targeted therapy and literature review | |
| Yalçin | The Relationsiıp Between Cancer and Ras Mutations | |
| Korkmaz et al. | Fifty-five months progression-free survival with crizotinib treatment in coexistence of ALK and ROS1 rearrangements in lung adenocarcinoma: an extremely rare case and review of the literature |